6月30日 - ** Pacira BioSciences（PCRX.O）股价在盘前交易中上涨3.8%，至26.05美元
** 这家制药公司将把其iovera业务出售给医疗器械制造商Zimmer Biomet（ZBH.N），交易金额最高达1.4亿美元，其中包括7000万美元的预付款，以及截至2031年最高7000万美元的里程碑付款
** Iovera是一种无需药物、利用冷疗法暂时阻断神经疼痛的医疗设备，适用于包括膝关节骨关节炎和膝关节置换手术相关的疼痛
** PCRX表示，ZBH将获得iovera的所有开发、制造和销售权
** 双方还将合作开展针对痉挛（即肌肉僵硬和抽搐）的治疗项目
** 该交易预计将于2026年第三季度完成，但须满足惯例条件
** 截至上一交易日收盘，PCRX今年以来累计下跌3.1%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.